Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004211 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target

NCT00004211: Completed Phase 1 study, sponsored by Duke University.

NCT00004211 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004211, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target

Study Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.

Interventions

  • BIOLOGICAL PSA RNA-pulsed dendritic cell vaccine

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 1999-07
Est. Completion 2002-01
Phase Phase 1
Duke University

1,725 total trials

What the finished NCT00004211 record still lists

NCT00004211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 1 intervention - of which PSA RNA-pulsed dendritic cell vaccine is the first listed.

NCT00004211 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00004211 about?

NCT00004211 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.

What is the current status of trial NCT00004211?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 1999-07. Estimated completion is 2002-01.

What interventions are being tested in trial NCT00004211?

The interventions under investigation include: PSA RNA-pulsed dendritic cell vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00004211?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00004211's enrollment target sits among peer trials

17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00004211, the US trial registry maintained by the National Library of Medicine. NCT00004211 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.